| Name | Title | Contact Details |
|---|
Ottobock was founded in Germany in 1919 by Otto Bock, a prosthetist. His vision of restoring mobility lives on today, growing to serve the world with more than 46 locations reaching more than 100 countries. The company is headquartered in Duderstadt, Germany, and has more than 5,000 employees. In the early 20th century, Otto Bock transformed the way prosthetic limbs were made. Instead of carving wood to fit a patient, he applied manufacturing techniques and created separate components (like knees and feet) that could be combined, altered or customized to create a limb that was still unique to each patient – but wasn’t built from scratch. Because of his pioneering work, Prosthetists were able to meet the demand generated by World War I and help veterans stay as active as possible. In 1958, our North American headquarters were established in Minneapolis, Minnesota. Our Canadian branch was founded in 1978 and is currently located in Toronto, Ontario. As the first branch, North America has led the way in advocating for and supporting local needs while still tapping into a global network of research and development, manufacturing, and clinical expertise. The people who use our products benefit from the synergy of a worldwide organization complemented by a local connection. Finally, Ottobock continues to give back to the community, supporting various charities and projects that are consistent with our mission of restoring independence.
Nemcomed is a Hicksville, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Milliken Medical is a Twinsburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medartis is a Kennett Square, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.